1. A combination of a compound of formula I: or a pharmaceutically acceptable salt thereof and means selected from GDC-0973, PD-0325901, or a pharmaceutically acceptable salt thereof, for preventing or treating a hyperproliferative narusheniya.2. A combination according to claim 1, wherein the hyperproliferative disorder is rak.3. A combination according to claim 2, wherein the cancer is associated with a mutation PTEN.4. A combination according to claim 2, wherein the cancer is associated with a mutation, overexpression or amplification AKT.5. A combination according to claim 2, wherein the cancer is associated with a mutation PI3K.6. The combination of claim 2 wherein the cancer associated with amplification of Her2 / ErbB2.7. Combination according to any one of claims. 2-6, where the cancer is selected from, mesothelioma, cancer of the endometrium, pancreas, breast, lung, ovarian, prostate, melanoma, stomach cancer, colon, kidney, head and neck and gliomy.8. Combination according to any one of claims. 1-6, wherein the compound of formula I, or a pharmaceutically acceptable salt thereof, is administered in combination with GDC-0973.9. Combination according to any one of claims. 1-6, wherein the compound of formula I, or a pharmaceutically acceptable salt thereof, is administered in combination with PD-0325901.10. Combination according to any one of claims. 1-6, wherein the compound of formula I or salt thereof is administered simultaneously with one or more sredstvami.11. Combination according to any one of claims. 1-6, wherein the compound of formula I or a salt thereof and one or more agents are administered posledovatelno.12. Combination according to any one of claims. 1-6, wherein the administration of one or more agents begin from about 1 to about 10 days prior to administration kombinatsii.13. Combination according to any one of claims. 1-6, wherein the administration of the compound of formula I or a salt thereof begin from about 1 to about 10 days prior to
